Exhibit 10.19


 


THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND,
EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS
AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY
TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION.


 


FORM OF WARRANT TO PURCHASE STOCK






 


Company: Clarus Therapeutics, Inc., a Delaware
corporation


Number of Shares: [    ]


Class of Stock: Series D Convertible Preferred
Stock, $0,001 par value per share


Warrant Price: $4.497407693, subject to adjustment


Issue Date: April 9,2013


Expiration Date: April 9, 2023


Credit Facility:
This Warrant is issued in connection with that certain Loan and Security Agreement of even date herewith among Silicon Valley Bank, Oxford
Finance LLC and the Company (as modified and/or amended and in effect from time to time, the “Loan Agreement”).


 


THIS WARRANT CERTIFIES THAT,
for good and valuable consideration, [       ]
(“[       ]”
and, together with any successor or permitted assignee or transferee of this Warrant or of any shares issued upon exercise hereof, “Holder”)
is entitled to purchase up to the above-stated number of fully paid and non-assessable shares (the “Shares”) of the above-stated
Class of Stock (the “Class”) of the above-named company (the “Company”), at a purchase price per Share equal to
the above-stated Warrant Price (the “Warrant Price”), subject to the adjustments and other provisions, and upon the terms
and conditions, set forth in this Warrant.


 


Article
1.  EXERCISE.


 


1.1
Method of Exercise. From and after the first date on which the Class is determinable pursuant to Paragraph A above, Holder
may exercise this Warrant by delivering the original of this Warrant together with a duly executed Notice of Exercise in substantially
the form attached as Appendix 1 to the principal office of the Company. Unless Holder is exercising the conversion right set forth in
Article 1.2, Holder shall also deliver to the Company a check, wire transfer (to an account designated by the Company), or other form
of payment acceptable to the Company for the aggregate Warrant Price for the Shares being purchased.


 


1.2
Conversion Right. In lieu of exercising this Warrant as specified in Article 1.1, Holder may from time to time convert
this Warrant, in whole or in part, into a number of Shares determined by dividing (a) the aggregate fair market value of the Shares or
other securities otherwise issuable upon exercise of this Warrant minus the aggregate Warrant Price of such Shares by (b) the fair market
value of one Share. The fair market value of the Shares shall be determined pursuant to Article 1.3.


 




     


     


    

 


1.3
 Fair Market Value. If the Company’s common stock is traded in a public market and Class is common stock, the fair
market value of a Share shall be the closing price of a share of common stock reported for the business day immediately before Holder
delivers this Warrant together with its Notice of Exercise to the Company (or in the instance where the Warrant is exercised immediately
prior to the effectiveness of the Company’s initial, underwritten offering and sale of its shares to the public pursuant to an effective
registration statement under the Securities Act of 1933, as amended (“IPO”), the “price to public” per share price
specified in the final prospectus relating to such offering). If the Company’s common stock is traded in a public market and the
Class is a series of convertible preferred stock, the fair market value of a Share shall be the closing price of a share of the Company’s
common stock reported for the business day immediately before Holder delivers this Warrant together with its Notice of Exercise to the
Company (or, in the instance where the Warrant is exercised immediately prior to the effectiveness of the IPO, the initial “price
to public” per share price specified in the final prospectus relating to such offering), in both cases, multiplied by the number
of shares of the Company’s common stock into which a share of the Class is convertible. If the Company’s common stock is not
traded in a public market, the Board of Directors of the Company shall determine fair market value in its reasonable good faith judgment.


 


1.4
Delivery of Certificate and New Warrant. Promptly after Holder exercises or converts this Warrant and, if applicable, the
Company receives payment of the aggregate Warrant Price, the Company shall deliver to Holder certificates for the Shares acquired and,
if this Warrant has not been fully exercised or converted and has not expired, a new warrant of like tenor representing the Shares not
so acquired.


 


1.5
Replacement of Warrants. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or
mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory
in form and amount to the Company or, in the case of mutilation, on surrender and cancellation of this Warrant, the Company shall execute
and deliver, in lieu of this Warrant, a new warrant of like tenor and amount.


 


1.6
Treatment of Warrant Upon Acquisition of Company.


 


1.6.1
“Acquisition”. For the purpose of this Warrant, “Acquisition” means any sale, assignment, transfer
or other disposition of all or substantially all of the assets of the Company, or any reorganization, consolidation or merger of the Company,
or sale of outstanding equity securities of the Company by the holders thereof, where the holders of the Company’s outstanding voting
equity securities as of immediately before the transaction beneficially own less than a majority of the outstanding voting equity securities
of the surviving or successor entity as of immediately after the transaction or, if such Company shareholders beneficially own a majority
of the outstanding voting equity securities of the surviving or successor entity as of immediately after the transaction, such surviving
or successor entity is not the Company.


 


1.6.2
Treatment of Warrant at Acquisition.


 


A)  
Holder agrees that, in the event of an Acquisition in which the sole consideration is cash and/or Marketable Securities, this Warrant
shall terminate on and as of the closing of such Acquisition to the extent not previously exercised. The Company shall provide Holder
with written notice of any proposed Acquisition not later than ten (10) days prior to the closing thereof setting forth the material terms and conditions
thereof, and shall provide Holder with copies of the draft transaction agreements and other documents in connection therewith and with
such other information respecting such proposed Acquisition as may reasonably be requested by Holder.


 




    2


     


    





 


B)
Upon the closing of any Acquisition other than as particularly described in subsection (A) above, the surviving or successor entity
shall assume this Warrant and the obligations of the Company hereunder, and this Warrant shall, from and after such closing, be exercisable
for the same class, number and kind of securities, cash and other property as would have been paid for or in respect of the Shares issuable
(as of immediately prior to such closing) upon exercise in full hereof as if such Shares had been issued and outstanding on and as of
such closing, at an aggregate Warrant Price equal to the aggregate Warrant Price in effect as of immediately prior to such closing; and
subject to further adjustment thereafter from time to time in accordance with the provisions of this Warrant.


 


C)  
As used in this Article 1.6, “Marketable Securities” means securities meeting all of the following requirements: (i)
the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”), and is then current in its filing of all required reports and other information under the
Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that would be received by Holder in connection
with the Acquisition were Holder to exercise or convert this Warrant on or prior to the closing thereof is then traded on a national securities
exchange or over-the-counter market, and (iii) Holder would not be restricted by contract or by applicable federal and state securities
laws from publicly re-selling, within six (6) months and one day following the closing of such Acquisition, all of the issuer’s
shares and/or other securities that would be received by Holder in such Acquisition were Holder to exercise or convert this Warrant in
full on or prior to the closing of such Acquisition.


 


1.7
Market “Stand-Off.” In connection with the IPO and upon request of the Company or the underwriters managing
such IPO, Holder shall not sell, make any short sale of, loan, grant any option for the purchase of, enter into any hedging or similar
transaction with the same economic effect as a sale, or otherwise dispose of any of the Company’s capital stock (or any securities
convertible into the Company’s capital stock) held by Holder, however or whenever acquired (other than those included in the registration
or purchased subsequent to the IPO) without the prior written consent of Company or such underwriters, as the case may be, for such period
of time (not to exceed one hundred and eighty (180) days, but subject to such extension or extensions as may be required by the underwriters
in order to publish research reports while complying with the then applicable rules of the Financial Industry Regulatory Authority, such
extension or extensions not to exceed thirty-four (34) days after the expiration of such 180-day period) from the effective date of such
registration statement as may be requested by the Company or such managing underwriters and to execute an agreement reflecting the foregoing
as may be requested by the underwriters at the time of the IPO. Holder agrees to execute and deliver such other agreements as may be reasonably
requested by the Company or the underwriter that are consistent with the Holder’s obligations under this Article 1.7 or that are
necessary to give further effect thereto. In addition, if requested by the Company or the representative of the underwriters of the Company’s
capital stock (or other securities) of the Company, Holder shall provide, within ten (10) days of such request, such information as may
be required by the Company or such representative in connection with the completion of any public offering of the Company’s securities
pursuant to a registration statement filed under the Securities Act. The underwriters of the Company’s stock are intended third
party beneficiaries of this Article 1.7 and shall have the right, power and authority to enforce the provisions hereof as though they were a party
hereto. The foregoing agreements of Holder in this Article 1.7 shall apply only if all directors and officers of the Company, and all
holders of one percent (1%) or more of the outstanding capital stock of the Company (calculated on a fully diluted basis), shall have
entered into agreements with the Company and/or underwriters substantially similar to such Holder agreements.


 




    3


     


    





 


Article
2.  ADJUSTMENTS TO THE
SHARES.


 


2.1
Stock Dividends, Splits, Etc. If the Company declares or pays a dividend on the outstanding shares of the Class payable
in common stock or other securities, then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without cost to
Holder, the total number and kind of securities to which Holder would have been entitled had Holder owned the Shares of record as of the
date the dividend occurred. If the Company subdivides the outstanding shares of the Class by reclassification or otherwise into a greater
number of shares, the number of Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately
decreased. If the outstanding shares of the Class are combined or consolidated, by reclassification or otherwise, into a lesser number
of shares, the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased.


 


2.2
Reclassification, Exchange, Conversion or Substitution. Upon any reclassification, exchange, conversion, substitution or
similar event affecting the outstanding shares of the Class, Holder shall be entitled to receive, upon exercise or conversion of this
Warrant, the number and kind of securities and property that Holder would have received for the Shares if this Warrant had been exercised
in full immediately before such reclassification, exchange, conversion, substitution or similar event, at an aggregate Warrant Price not
exceeding the aggregate Warrant Price in effect as of immediately prior thereto. Such an event shall include, without limitation, any
automatic or voluntary conversion of all outstanding shares of the Class to common stock pursuant to the terms of the Company’s
Certificate of Incorporation. The Company or its successor shall promptly issue to Holder a certificate pursuant to Article 2.6 hereof
setting forth the number, class and series or other designation of such new securities or other property issuable upon exercise or conversion
of this Warrant as a result of such reclassification, exchange, conversion, substitution or similar event. The provisions of this Article
2.2 shall similarly apply to successive reclassifications, exchanges, conversions, substitutions, and similar events.


 


2.3
Adjustments for Diluting Issuances. Without duplication of any adjustment otherwise made pursuant to this Article 2, the
number of shares of common stock issuable upon conversion of the Shares shall be subject to adjustment from time to time in the manner
set forth in the Company’s Certificate of Incorporation as if the Shares were issued and outstanding on and as of the date of any
such required adjustment. The provisions set forth for the Class in the Company’s Certificate of Incorporation relating to the above
in effect as of the Issue Date may not be amended, modified or waived, without the prior written consent of Holder unless such amendment,
modification or waiver affects the rights associated with the Shares in the same manner as such amendment, modification or waiver affects
the rights associated with all other shares of the Class.


 


2.4
No Impairment. The Company shall not, by amendment of its Certificate of Incorporation or through a reorganization, transfer
of assets, consolidation, merger, dissolution, issue, or sale of securities or any other voluntary action, avoid or seek to avoid the
observance or performance of any of the terms to be observed or performed under this Warrant by the Company, but shall at all times in good
faith assist in carrying out of all the provisions of this Article 2 and in taking all such action as may be necessary or appropriate
to protect Holder’s rights under this Article against impairment.


 




    4


     


    





 


2.5
Fractional Shares. No fractional Share shall be issuable upon exercise or conversion of the Warrant and the number of Shares
to be issued shall be rounded down to the nearest whole Share. If a fractional share interest arises upon any exercise or conversion of
the Warrant, the Company shall eliminate such fractional share interest by paying Holder the amount computed by multiplying the fractional
interest by the fair market value (as determined pursuant to Article 1.3 above) of a full Share.


 


2.6
Certificate as to Adjustments. Upon each adjustment of the Warrant Price, Class and/or number of Shares, the Company shall
promptly notify Holder in writing, and, at the Company’s expense, promptly compute such adjustment, and furnish Holder with a certificate
of its Chief Financial Officer setting forth such adjustment and the facts upon which such adjustment is based. The Company shall, upon
written request, furnish Holder a certificate setting forth the Warrant Price, Class and number of Shares in effect upon the date thereof
and the series of adjustments leading to such Warrant Price, Class and number of Shares.


 


Article
3.  REPRESENTATIONS AND
COVENANTS OF THE COMPANY.


 


3.1
Representations and Warranties. The Company represents and warrants to, and agrees with, the Holder as follows:


 


(a)
The initial Warrant Price first set forth above is not greater than the price per share at which shares of the Class were last
issued in an arms-length transaction in which at least $500,000 of such shares were sold.


 


(b)
The Company shall at all times during the term of this Warrant keep reserved out of its authorized and unissued capital stock a
sufficient number of shares of the Class (and, if the Class is a series of convertible preferred stock, a sufficient number of shares
of common stock) to permit exercise in full of this Warrant and, if applicable, conversion of the Shares issuable and issued upon any
exercise hereof. All Shares which may be issued upon the exercise or conversion of this Warrant shall, upon issuance, be duly authorized,
validly issued, fully paid and non-assessable, and free of any liens and encumbrances except for restrictions on transfer provided for
herein or under applicable federal and state securities laws.


 


(c)
The Company’s capitalization table attached hereto as Schedule 1 is true and complete as of the Issue Date.


 


3.2
Notice of Certain Events. If the Company proposes at any time (a) to declare any dividend or distribution upon the outstanding
shares of the Class, whether in cash, property, stock, or other securities and whether or not a regular cash dividend; (b) to offer for
subscription or sale pro rata to the holders of the outstanding shares of the Class any additional shares of any class or series of the
Company’s stock (other than pursuant to contractual pre-emptive rights); (c) to effect any event described in Article 2.2 above,
or (d) to effect an Acquisition or to liquidate, dissolve or wind up; then, in connection with each such event, the Company shall give
Holder: (1) at least 10 days prior written notice of the date on which a record will be taken for such dividend, distribution, or subscription
rights (and specifying the date on which the holders of shares of the Class will be entitled thereto) or for determining rights to vote,
if any, in respect of the matters referred to in (c) and (d) above; and (2) in the case of the matters referred to in (c) and (d) above at least
10 days prior written notice of the date when the same will take place (and specifying the date on which the holders of shares of the
Class will be entitled to exchange their shares for the securities or other property deliverable upon the occurrence of such event).


 




    5


     


    





 


3.3
[Intentionally Omitted].


 


3.4
No Shareholder Rights. Except as provided in this Warrant, Holder will not have any rights as a shareholder of the Company
until the exercise or conversion of this Warrant.


 


3.5
Certain Information. The Company agrees to provide Holder at any time and from time to time with such information as Holder
may reasonably request for purposes of Holder’s compliance with regulatory, accounting and reporting requirements applicable to
Holder.


 


Article
4.  REPRESENTATIONS,
WARRANTIES OF THE HOLDER. The Holder represents and warrants to the Company as follows:


 


4.1
Purchase for Own Account. This Warrant and the securities to be acquired upon exercise of this Warrant by Holder will be
acquired for investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution
within the meaning of the Act. Holder also represents that it has not been formed for the specific purpose of acquiring this Warrant or
the Shares.


 


4.2
Disclosure of Information. Holder has received or has had full access to all the information it considers necessary or appropriate
to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities. Holder further
has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this
Warrant and its underlying securities and to obtain additional information (to the extent the Company possessed such information or could
acquire it without unreasonable effort or expense) necessary to verify any information furnished to Holder or to which Holder has access.


 


4.3
Investment Experience. Holder understands that the purchase of this Warrant and its underlying securities involves substantial
risk. Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the
economic risk of such Holder’s investment in this Warrant and its underlying securities and has such knowledge and experience in
financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying
securities and/or has a preexisting personal or business relationship with the Company and certain of its officers, directors or controlling
persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such
persons.


 


4.4
Accredited Investor Status. Holder is an “accredited investor” within the meaning of Regulation D promulgated
under the Act.


 


4.5
The Act. Holder understands that this Warrant and the Shares issuable upon exercise or conversion hereof have not been registered
under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature
of the Holder’s investment intent as expressed herein. Holder understands that this Warrant and the Shares issued upon any exercise
or conversion hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities
laws, or unless exemption from such registration and qualification are otherwise available.


 




    6


     


    





 


Article
5.  MISCELLANEOUS.


 


5.1
Term: This Warrant is exercisable in whole or in part at any time and from time to time on or before 6:00 PM Pacific time
on the Expiration Date first set forth above, and shall be void thereafter.


 


5.2
Legend. Each certificate representing Shares issued upon any exercise or conversion hereof (and the certificates representing
the securities issued upon conversion of such Shares, if any) shall be imprinted with a legend in substantially the following form:


 


THE SECURITIES REPRESENTED BY THIS CERTIFICATE
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND,
EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 OF THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE COMPANY TO [     ]
DATED AS OF APRIL 9, 2013, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER
SAID ACT AND APPLICABLE STATE SECURITIES LAW OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE
SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION.


 


5.3
Compliance with Securities Laws on Transfer. This Warrant and the Shares issuable upon exercise of this Warrant (and the
securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in
part without compliance with applicable federal and state securities laws by the transferor and the transferee (including, without limitation,
the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by
the Company). The Company shall not require Holder to provide an opinion of counsel if the transfer is to any affiliate of Holder, provided
that [any] such [transferee][affiliate] is an “accredited investor” as defined in Regulation D promulgated under the Act.


 


5.4
Transfer Procedure. [Following the issuance][After receipt by [    ]
of the executed Warrant, Bank will transfer all] of this Warrant to [[     ],
[     ] may transfer same in whole or
in part to one or more affiliates of , and in connection with any such transfer [     ]
and the affiliate transferee shall execute and deliver to the Company an Assignment substantially in the form of Appendix 2 hereto][Holder’s
parent company]. Subject to the provisions of Article 5.3 and upon providing the Company with written notice, such [     ]
affiliate and any subsequent Holder may transfer all or part of this Warrant or the Shares [issued][issuable] upon exercise of this Warrant
(or the securities [issued][issuable directly or indirectly] upon conversion of the Shares, if any) to any transferee, provided, however,
in connection with any such transfer, such [     ]
affiliate or any subsequent Holder will give the Company notice of the portion of the Warrant [and/or Shares (and/or securities issued
upon conversion of the Shares, if any)] being transferred with the name, address and taxpayer identification number of the transferee
and Holder will surrender this Warrant to the Company for reissuance to
the transferee(s) (and Holder if applicable). The Company may refuse to transfer this Warrant or the Shares to any person who directly
competes with the Company, unless, in either case, the stock of the Company is publicly traded.


 




    7


     


    





 


5.5
Notices. All notices and other communications hereunder from the Company to the Holder, or vice versa, shall be deemed delivered
and effective (i) when given personally, (ii) on the third (3rd) Business Day after being mailed by first- class registered or certified
mail, postage prepaid, (iii) upon actual receipt if given by facsimile or electronic mail and such receipt is confirmed in writing by
the recipient, or (iv) on the first Business Day following delivery to a reliable overnight courier service, courier fee prepaid, in any
case at such address as may have been furnished to the Company or Holder, as the case may be, in writing by the Company or such Holder
from time to time in accordance with the provisions of this [Article][Section] 5.5. All notices to Holder shall be addressed as follows
until the Company receives notice of a change of address in connection with a transfer or otherwise:


 


[    ]

[    ]

Attn:[     ]

Telephone:

Facsimile









Notice to the Company shall
be addressed as follows until Holder receives notice of a change in address:


 


Clarus Therapeutics, Inc.

Attn: Steve Bourne, Chief Financial Officer

555 Skokie Boulevard, Suite 340

Northbrook, IL 60062

Telephone: 847-562-4300

Facsimile: 847-562-4306

Email:


 


With a copy (which shall not
constitute notice) to:


 


Goodwin Procter LLP

Attn: Mark D. Smith, Esq.

Exchange Place 53 State Street

Boston, MA 02109

Telephone: (617) 570-1750

Facsimile: (617) 523-1231

Email: marksmith@goodwinprocter.com


 


5.6
Waiver. This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing
signed by the party against which enforcement of such change, waiver, discharge or termination is sought.


 




    8


     


    


 


5.7
 Attorneys’ Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant,
the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable
attorneys’ fees and disbursements.


 


5.8
Automatic Conversion upon Expiration. In the event that, upon the Expiration Date, the fair market value of one Share (or
other security issuable upon the exercise hereof) as determined in accordance with Article 1.3 above is greater than the Warrant Price
in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be converted pursuant to Article 1.2
above as to all Shares (or such other securities) for which it shall not previously have been exercised or converted, and the Company
shall promptly deliver a certificate representing the Shares (or such other securities) issued upon such conversion to Holder.


 


5.9
Counterparts. This Warrant may be executed in counterparts, all of which together shall constitute one and the same agreement.


 


5.10  
Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of Delaware, without
giving effect to its principles regarding conflicts of law.


 


[Remainder of page left blank intentionally;
signature page follows]


 




    9


     


    


 


IN WITNESS WHEREOF, the parties
have executed this Warrant to Purchase Stock by their duly authorized representatives as of the date first above written.


 


	COMPANY	 
	 	 
	CLARUS THERAPEUTICS, INC.	 
	 	 
	By:	                                	 
	 	 
	Name:	 	 
	 	(Print)	 
	 	 	 
	Title:	 	 
	 	 
	HOLDER	 
	[                                      ]	
	 	 
	By:	 	 
	 	 
	Name:	 	 
	 	(Print)	 
	Title:	 	 



 




    10


     


    


 


APPENDIX 1


 


NOTICE OF EXERCISE


 


1.   Holder
elects to purchase ____________ shares of the Common/Series ______ Preferred [strike one] Stock of _________________ pursuant to the terms
of the attached Warrant, and tenders payment of the purchase price of the shares in full.


 


[or]


 


1.   Holder
elects to convert the attached Warrant into Shares/cash [strike one] in the manner specified in the Warrant. This conversion is exercised
for __________________________ of the Shares covered by the Warrant.


 


[Strike paragraph that does
not apply.]


 


2.   Please
issue a certificate or certificates representing the Shares in the name specified below:


 





	 	 	 
	 	Holders Name	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	(Address)	 


 


3.   By
its execution below and for the benefit of the Company, Holder hereby restates each of the representations and warranties in Article 4
of the Warrant as of the date hereof.


 





	 	HOLDER:
	 	 	 
	 	 
	 	 	 
	 	By:	     
	 	Name:	 
	 	Title:	 
	 	(Date):	 


 




    11


     


    


 


APPENDIX 2


 


FORM OF ASSIGNMENT


 


For value received [     ],
hereby sells, assigns and transfers unto


 


	Name:  [	TRANSFEREE]	 
	Address:	 	 
	 	 	 
	Tax ID:	 	 






 


that certain Warrant to Purchase Stock issued
by [BORROWER] (the “Company”), on [ISSUE DATE] (the “Warrant”) together with all rights, title and interest therein.


 


		[                  ]
	 	 
		By:	                   
		Name:	 
		Title:	 
	Date: _______________________________	 









 


By its execution below, and for the benefit of
the Company, [ TRANSFEREE] hereby makes each of the representations and warranties set forth in Article 4 of the Warrant as of the date
hereof and agrees to be bound by all provisions of the Warrant as the Holder thereof.


 





		[
TRANSFEREE]
	 	 
		By:	                   
		Name:	 
		Title:	 
		 


 







    12


     


    


 


AMENDMENT NO. 1 TO WARRANT TO PURCHASE COMMON
STOCK


 


THIS AMENDMENT NO. 1
TO WARRANT TO PURCHASE COMMON STOCK (this “Amendment No. 1”) is made this 21st day of April, 2021,
by and between (“Holder”) and Clarus Therapeutics, Inc., a Delaware corporation (the “Company”).


 


WHEREAS, on April 9,
2013, the Company issued that certain Warrant to Purchase [Common Stock][ shares of Series D Convertible Preferred Stock] (the “Warrant”)
to [      ]
and the Company and Holder now desire to amend the Warrant as set forth below.


 


NOW, THEREFORE, in consideration
of the premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties
agree as follows:


 


Article
6.  Amendment of Warrant.
The Warrant is hereby amended by inserting the following paragraph D under Section 1.6.2:


 


“D) Upon the closing of a merger of the
Company with a special purpose acquisition company with a class of securities registered under the Securities Exchange Act of 1934 (a
“SPAC”), or a subsidiary thereof, in which the holders of the Company’s outstanding voting equity securities
as of immediately before the merger beneficially own a majority of the outstanding voting equity securities of the SPAC following the
merger (a “SPAC Acquisition”), the SPAC shall assume this Warrant and the obligations of the Company hereunder, and
this Warrant shall, from and after such closing, be exercisable for the same class, number and kind of securities of the SPAC as would
have been paid for or in respect of the Shares issuable (as of immediately prior to such closing) upon exercise in full hereof as if such
Shares had been issued and outstanding on and as of such closing, at an aggregate Warrant Price equal to the aggregate Warrant Price in
effect as of immediately prior to such closing; and subject to further adjustment thereafter from time to time in accordance with the
provisions of the Warrant. Promptly following the closing of a SPAC Acquisition, the Company shall, as set forth in Section 2.6,
deliver a certificate of its Chief Financial Officer to Holder.”


 


Article
7.  No Other Amendments.
Except as amended hereby, the Warrant shall remain in full force and effect as originally written.


 


Article
8.  Governing Law.
This Amendment No. 1 shall be governed by and construed with the laws of the State of Delaware, without giving effect to its principles
regarding conflicts of laws.


 


Article
9.  Counterparts.
This Warrant may be executed in counterparts, all of which together constitute one and the same agreement. Each party hereto may execute
this Amendment No. 1 by electronic means.


 


[Remainder of page intentionally blank]


 




    13


     


    


 


IN WITNESS WHEREOF, the parties have executed
this Amendment No. 1 by their duly authorized representatives as of the date first above written.


 


	COMPANY	 
	 	 
	CLARUS THERAPEUTICS, INC.	 
	 	 
	By:	                                    	 
	 	 
	Name:	 	 
	 	 
	Title:	 	 
	 	 
	HOLDER	 
	[                                       ]	
	By:	 	 
	 	 
	Name:	 	 
	 	 
	Title:	 	 



 


 


14